ppt课件-thetriumphstudy-clinicaltrialresults.pptVIP

The Tilarginine Acetate Injection in a Randomized International Study in Unstable Acute Myocardial Infarction Patients with Cardiogenic Shock (TRIUMPH) Background The incidence of cardiogenic shock complicating STEMI has remained stable at ~8% Despite the reduction in mortality resulting from early revascularization, early mortality rates remain high (50% at 30 days) Background A systemic inflammatory response syndrome (SIRS) may be triggered by a large MI, with elevation of inflammatory cytokines (e.g.,IL-6), as seen in septic shock High cytokine levels are associated with the development